Evidence map›Paper›PMID 32272736›Full record

ArticleBiomedicines2020

Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C.

Karen K Kyuregyan, Vera S Kichatova, Anastasiya A Karlsen, Olga V Isaeva, Sergei A Solonin, Stefan Petkov, Morten Nielsen, Maria G Isaguliants, Mikhail I Mikhailov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karen K KyuregyanRussian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.
Vera S KichatovaRussian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.
Anastasiya A KarlsenRussian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.
Olga V IsaevaRussian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.
Sergei A SoloninN.V. Sklifosovsky Research Institute for Emergency Medicine, 129090 Moscow, Russia.
Stefan PetkovDepartment of Microbiology, Tumor and Cell Biology, Biomedicum, Karolinska Institute, 17165 Solna, Sweden.
Morten NielsenInstituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, San Martín CP1650, Argentina.
Maria G IsaguliantsChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Mikhail I MikhailovRussian Medical Academy of Continuous Professional Education, 125993 Moscow, Russia.

Funding

Latvian Science Council LZP-2018/2-0308Russian Science Foundation 15-15-30039
6 · The paper itself

Abstract

Direct-acting antivirals (DAAs) revolutionized treatment of hepatitis C virus (HCV) infection. Resistance-associated substitutions (RASs) present at the baseline impair response to DAA due to rapid selection of resistant HCV strains. NS5A is indispensable target of the current DAA treatment regimens. We evaluated prevalence of RASs in NS5A in DAA-naïve patients infected with HCV 1a (

Indexed as

amino acid covariancedirect-acting antiviralshepatitis C virus (HCV)immune escapeNS5Aresistance-associated substitutions

Identifiers

PMID32272736
PMCPMC7235841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.